Stereotactic Ablative Radiotherapy for the Treatment of Upper Urinary Tract Urothelial Carcinoma

AbstractThis study aims to compare oncologic and functional outcomes after radical nephroureterectomy (RNU) and segmental ureterectomy (SU) in patients with upper urinary tract urothelial carcinoma (UTUC). We retrospectively collected data on patients who underwent either RNU or SU of UTUC. Propensity score matching was performed among 394 cases to yield a final cohort of 40 RNU and 40 SU cases. Kaplan–Meier analysis and the log-rank test were used to compare overall survival (OS), cancer-specific survival (CSS), progression-free survival (PFS), and intravesical recurrence-free survival (IVRFS) between the groups. We also compared the change in postoperative estimated glomerular filtration rate (eGFR). There was no significant difference in terms of CSS, PFS, and IVRFS between the RNU and SU groups, but the RNU group had a better OS than the SU group (p = 0.032). Postoperative eGFR was better preserved in the SU group than in the RNU group (p < 0.001). SU provides comparable CSS, PFS, and IVRFS for patients with UTUC compared to RNU, even in patients with advanced-stage and/or high-grade cancer. Further, SU achieves better preservation of renal function.

Download Full-text

Rising incidence rates and unaltered survival for primary upper urinary tract urothelial carcinoma: a Dutch population‐based study from 1993 to 2017.

BJU International ◽

10.1111/bju.15389 ◽

2021 ◽

Author(s):

Thomas van Doeveren ◽

Marianne van der Mark ◽

Pim J. van Leeuwen ◽

Joost L. Boormans ◽

Katja K.H. Aben

Keyword(s):

Urinary Tract ◽

Urothelial Carcinoma ◽

Population Based ◽

Upper Urinary Tract ◽

Incidence Rates ◽

Dutch Population ◽

Population Based Study ◽

Rising Incidence ◽

Urinary Tract Urothelial Carcinoma

Download Full-text

Concurrent chemoradiotherapy in patients with non‐metastatic upper urinary tract urothelial carcinoma: Report from a single institution in Taiwan

International Journal of Urology ◽

10.1111/iju.14112 ◽

2019 ◽

Vol 27 (1) ◽

pp. 83-84

Author(s):

Nai‐Wen Kang ◽

Kuei‐Li Lin ◽

Kuan‐Hua Huang ◽

Kun‐Hung Shen ◽

Chung‐Han Ho ◽

...

Keyword(s):

Urinary Tract ◽

Urothelial Carcinoma ◽

Concurrent Chemoradiotherapy ◽

Upper Urinary Tract ◽

Single Institution ◽

Urinary Tract Urothelial Carcinoma

Download Full-text

Combination of pembrolizumab and BCG treatment after endoscopic ablation of high-risk superficial upper urinary tract urothelial carcinoma in patients not candidates for radical nephroureterectomy: protocol for phase-II study

BMJ Open ◽

10.1136/bmjopen-2018-027066 ◽

2019 ◽

Vol 9 (12) ◽

pp. e027066

Author(s):

Marcus L Jamil ◽

Mustafa Deebajah ◽

Akshay Sood ◽

Shaheen Alanee

Keyword(s):

Urinary Tract ◽

High Risk ◽

Urothelial Carcinoma ◽

Phase Ii ◽

Upper Urinary Tract ◽

Fixed Dose ◽

Radical Nephroureterectomy ◽

Safety And Efficacy ◽

Muscle Invasive ◽

Urinary Tract Urothelial Carcinoma

IntroductionThe treatment standard for high-risk upper urinary tract urothelial carcinoma (UUTUC) is radical nephroureterectomy. However, some patients may be unfit or unwilling, and in such patients the available alternatives are suboptimal. Therapies targeting the programmed death (PD) pathway have shown promise in urothelial carcinom (UC). We designed the current study to determine the safety and efficacy of administering MK-3475 (a monoclonal antibody targeting interaction between PD-1 and its ligand) in combination with bacillus Calmette-Guerin (BCG) in high-risk non-muscle invasive UUTUC patients.MethodsThis represents a single-centre phase-II efficacy study of MK-3475 therapy in combination with BCG for subjects, 18 years of age or older, with pathologically documented non-muscle invasive high-risk UUTUC unfit or unwilling to be treated with radical nephroureterectomy. Twenty subjects will be enrolled; patients will receive treatment with 200 mg of MK-3475 every 21 days, starting 2 weeks from the initial endoscopic resection and continuing for 6 weeks after the final dose of BCG. The primary objective is to determine the safety and efficacy of administering MK-3475 at a fixed dose of 200 mg every 3 weeks in conjunction with intrapelvic BCG. Secondary objectives include 19 week and the 3, 12 and 24-month post-treatment completion complete response and progression-free rate assessments.Ethics and disseminationThe study has been approved by the Institutional Review Board of the Henry Ford Hospital. The results of this study will be published in a peer-reviewed journal and presented at a scientific conference.Trial registration numberNCT03345134

Download Full-text